Stem Cells Market Will Reach USD 119.51 Billion in 2018: Transparency Market Research
Username or Email Address
Do you already have an account?
Forgot your password?
  • Log in or Sign up

    Welcome to InvestorStemCell
    The Future is NOW! Be a part of the Future of Medicine and join the InvestorStemCell Community! InvestorStemCell is the worlds only community dedicated to Regenerative Medicine. Get started by signing up!
    Results 1 to 13 of 13
    Like Tree53Likes
    • 19 Post By Peter Vaguely
    • 4 Post By ablidy
    • 2 Post By GMAN
    • 4 Post By stemdynasty
    • 1 Post By NOLAstemcell
    • 1 Post By RufusT
    • 5 Post By froggy
    • 4 Post By AZ geologist
    • 8 Post By stemdynasty
    • 3 Post By froggy
    • 2 Post By Waterbuglover

    Stem Cells Market Will Reach USD 119.51 Billion in 2018: Transparency Market Research

    1. #1
      Peter Vaguely's Avatar

      Stem Cells Market Will Reach USD 119.51 Billion in 2018: Transparency Market Research

      Stem Cells Market Will Reach USD 119.51 Billion in 2018: Transparency Market Research
      Stem Cells Market Will Reach USD 119.51 Billion in 2018: Transparency Market Research - SFGate


      ACTC Mentioned

      "According to a new market report published by Transparency Market Research, “Stem Cells Market (Adult, Human Embryonic , Induced Pluripotent, Rat-Neural, Umbilical Cord, Cell Production, Cell Acquisition, Expansion, Sub-Culture)- Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2012 - 2018,“ the market for stem cells was valued at USD 26.23 billion in 2011 and is expected to reach an estimated value of USD 119.51 billion in 2018, growing at a CAGR of 24.2% from 2012 to 2018."

      "The key players in stem cell research and technology include Advanced Cell Technology Inc., Stem Cell Technologies Inc., Cellular Engineering Technologies Inc., BioTime Inc., and Cellartis Ab among others."
      stemedga, GMAN, k00ij and 16 others like this.

    2. #2
      ablidy's Avatar
      wonder how much of that is going to be ACTc?
      Ask immunologic questions give molecular answers

    3. #3
      GMAN's Avatar
      The numbers just keep going up...
      ablidy and kokway like this.
      "Those who are able to see beyond the shadows and lies of their culture will never be understood, let alone believed by the masses" Plato


    4. #4
      stemdynasty
      Guest stemdynasty's Avatar
      That's a big number and makes the case for hedge funds to begin to look closer at reg med. It also makes for partnerships and takeovers. I simply can't fathom what the number would be if we were fully funded, had the manpower, the facilities, and the ability to fast track some of these CURES.

    5. #5
      Supreme Member NOLAstemcell's Avatar
      Not that I was ever going to sell, but research likes this just confirms how devastated I would be if that $120B in the industry pans out, and I had no shares or equity to show for it because I was worried when one day in 2013 my stock was down 10%. Sign me up.
      WANT2RETIRE likes this.

    6. #6
      Partner Member RufusT's Avatar
      Peter, your old dancing Sierra Madre man makes me smile every time I see him. I've been practicing that jig. Now I just hope the treasure changes us all for the good!
      Last edited by RufusT; 08-20-2013 at 06:17 PM.
      kokway likes this.

    7. #7
      froggy's Avatar
      So we are the leader but in spite of that what if we only got 20% of the market? 20% of $120b is 24b. On revenue of around 10b novartis has a market cap of 200b. A multiple of twenty times. Roche's multiple is also around 20. So our multiple at 24b would be over 400b. Pretty freaky stuff.QUOTE=Peter Vaguely;168948]Stem Cells Market Will Reach USD 119.51 Billion in 2018: Transparency Market Research
      Stem Cells Market Will Reach USD 119.51 Billion in 2018: Transparency Market Research - SFGate


      ACTC Mentioned

      "According to a new market report published by Transparency Market Research, “Stem Cells Market (Adult, Human Embryonic , Induced Pluripotent, Rat-Neural, Umbilical Cord, Cell Production, Cell Acquisition, Expansion, Sub-Culture)- Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2012 - 2018,“ the market for stem cells was valued at USD 26.23 billion in 2011 and is expected to reach an estimated value of USD 119.51 billion in 2018, growing at a CAGR of 24.2% from 2012 to 2018."

      "The key players in stem cell research and technology include Advanced Cell Technology Inc., Stem Cell Technologies Inc., Cellular Engineering Technologies Inc., BioTime Inc., and Cellartis Ab among others."[/QUOTE]

    8. #8
      AZ geologist's Avatar
      Quote Originally Posted by froggy View Post
      So we are the leader but in spite of that what if we only got 20% of the market? 20% of $120b is 24b. On revenue of around 10b novartis has a market cap of 200b. A multiple of twenty times. Roche's multiple is also around 20. So our multiple at 24b would be over 400b. Pretty freaky stuff.
      And to take that analysis one step further, based on today's share structure, that comes out to a pre-R/S price of ~$38/share. Owners with fewer than ~27000 shares today (again pre-R/S) would end up millionaires. Not a bad return for a stock that's six and a half cents today.

      EDIT: Updated figures to reflect Stargazer's more conservative Google Finance-derived numbers. Still looks great.
      Last edited by AZ geologist; 08-20-2013 at 07:57 PM.


    9. #9
      Stargazer's Avatar
      Quote Originally Posted by froggy View Post
      On revenue of around 10b novartis has a market cap of 200b.
      Froggy, Google Finance states that Novartis' 2012 year end revenue was 57.5B and the current mcap is 183B so the mcap/sales multiple is 3.2 and not 20. Also the mcap/sales multiple for Roche is 4.5 and not 20.

      So using your rationale if ACTC's achieves a revenue of 24B, its mcap would be in the range of 100B (using the average of NVS and Roche multiples)

    10. #10
      stemdynasty
      Guest stemdynasty's Avatar
      Our market cap is around 155 million today. This isn't getting in at the ground floor, more like bargain basement. Think in terms of generational wealth. We are the epitomy of true investors..... Warren Buffett style. Recognize a great company, buy on sale, load up, and hold. Let others chase it when they figure it out what you already know. Stay the course.

    11. #11
      froggy's Avatar
      I was looking at PE ratios so you are correct. the novartis PE is 19.6 and the Roche PE is 18.6. But it does appear that at least with the eye program that $100 cost per dose will get us a very significant earnings per cent of revenue.
      Quote Originally Posted by Stargazer View Post
      Froggy, Google Finance states that Novartis' 2012 year end revenue was 57.5B and the current mcap is 183B so the mcap/sales multiple is 3.2 and not 20. Also the mcap/sales multiple for Roche is 4.5 and not 20.

      So using your rationale if ACTC's achieves a revenue of 24B, its mcap would be in the range of 100B (using the average of NVS and Roche multiples)
      Stargazer, saxxie and fred1947dy like this.

    12. #12
      Waterbuglover's Avatar
      Who’s the first company listed?

      If ACTC treats 1,000,000 people at $10,000/eye a year they get $20 billion of the $120 billion market.

      Their cost /eye $100 ( 99% profit margin).

      30,000,000 million people have AMD. After issuing new shares. Their profit will only be:

      3.75 billion shares/ $19.8 billion = $5.28/share profit. What do you think the share price will be in 5 years?

      Must be drinking way to much Koolaid.
      saxxie and fred1947dy like this.

    13. #13
      stemdynasty
      Guest stemdynasty's Avatar
      Ask Dr Knoepfler that seems to have a functioning crystal ball into our future.

    Tags for this Thread